References analysis of the Wikipedia article "Repinotan" in the English version

doi.org

Alessandri B, Tsuchida E, Bullock RM (October 1999). "The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat". Brain Research. 845 (2): 232–235. doi:10.1016/S0006-8993(99)01948-4. PMID 10536203. S2CID 36341439.

Kline AE, Yu J, Horváth E, Marion DW, Dixon CE (2001). "The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats". Neuroscience. 106 (3): 547–555. doi:10.1016/S0306-4522(01)00300-1. PMID 11591455. S2CID 54308982.

Mauler F, Horváth E (April 2005). "Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury". Journal of Cerebral Blood Flow and Metabolism. 25 (4): 451–459. doi:10.1038/sj.jcbfm.9600038. PMID 15674237.

Ohman J, Braakman R, Legout V, et al. (Traumatic Brain Injury Study Group) (December 2001). "Repinotan (BAY x 3702): a 5HT1A agonist in traumatically brain injured patients". Journal of Neurotrauma. 18 (12): 1313–1321. doi:10.1089/08977150152725614. PMID 11780862.

Lutsep HL (April 2005). "Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke". Current Drug Targets. CNS and Neurological Disorders. 4 (2): 119–120. doi:10.2174/1568007053544165. PMID 15857296.

Berends AC, Luiten PG, Nyakas C (2005). "A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) in ischemic stroke". CNS Drug Reviews. 11 (4): 379–402. doi:10.1111/j.1527-3458.2005.tb00055.x. PMC 6741728. PMID 16614737.

Teal P, Davis S, Hacke W, Kaste M, Lyden PD, Fierus M, et al. (Modified Randomized Exposure Controlled Trial Study Investigators) (November 2009). "A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT)". Stroke. 40 (11): 3518–3525. doi:10.1161/STROKEAHA.109.551382. PMID 19745176.

Guenther U, Wrigge H, Theuerkauf N, Boettcher MF, Wensing G, Zinserling J, et al. (October 2010). "Repinotan, a selective 5-HT1A-R-agonist, antagonizes morphine-induced ventilatory depression in anesthetized rats". Anesthesia and Analgesia. 111 (4): 901–907. doi:10.1213/ANE.0b013e3181eac011. PMID 20802053. S2CID 39217801.

Kline AE, Yu J, Horváth E, Marion DW, Dixon CE (2001). "The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats". Neuroscience. 106 (3): 547–555. doi:10.1016/s0306-4522(01)00300-1. PMID 11591455. S2CID 54308982.

Teal P, Davis S, Hacke W, Kaste M, Lyden PD, Fierus M (November 2009). "A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT)". Stroke. 40 (11): 3518–3525. doi:10.1161/strokeaha.109.551382. PMID 19745176.

Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R (July 2006). "5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease". Neurobiology of Disease. 23 (1): 77–86. doi:10.1016/j.nbd.2006.02.003. hdl:10261/59551. PMID 16545572. S2CID 19803633.

Ferro JM, Dávalos A (2006). "Other neuroprotective therapies on trial in acute stroke". Cerebrovascular Diseases. 21 Suppl 2 (2): 127–130. doi:10.1159/000091712. PMID 16651823. S2CID 39193793.

Teal P, Silver FL, Simard D (February 2005). "The BRAINS study: safety, tolerability, and dose-finding of repinotan in acute stroke". The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques. 32 (1): 61–67. doi:10.1017/s0317167100016899. PMID 15825548.

Boettcher M, Heinig R, Wensing G, Kuhlmann J (March 2005). "Pupil reaction: a valid sensitive clinical biomarker for 5-HT compounds". Basic & Clinical Pharmacology & Toxicology. 96 (3): 246. doi:10.1111/j.1742-7843.2005.pto960317.x. PMID 15733223.

Tanigawa T, Heinig R, Kuroki Y, Higuchi S (February 2006). "Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach" (PDF). Drug Metabolism and Pharmacokinetics. 21 (1): 61–69. doi:10.2133/dmpk.21.61. PMID 16547395. S2CID 10517194. Archived from the original (PDF) on 2020-02-07.

Adayev T, Ray I, Sondhi R, Sobocki T, Banerjee P (April 2003). "The G protein-coupled 5-HT1A receptor causes suppression of caspase-3 through MAPK and protein kinase Calpha". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1640 (1): 85–96. doi:10.1016/s0167-4889(03)00023-5. PMID 12676358.

Díaz-Mataix L, Artigas F, Celada P (May 2006). "Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by a 5-HT1A receptor agonist". European Neuropsychopharmacology. 16 (4): 288–296. doi:10.1016/j.euroneuro.2005.10.003. hdl:10261/34586. PMID 16290106. S2CID 38788669.

Díaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F (November 2005). "Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action". The Journal of Neuroscience. 25 (47): 10831–10843. doi:10.1523/jneurosci.2999-05.2005. PMC 6725886. PMID 16306396.

Schwarz T, Beckermann B, Buehner K, Mauler F, Schuhmacher J, Seidel D, et al. (September 2005). "Pharmacokinetics of repinotan in healthy and brain injured animals". Biopharmaceutics & Drug Disposition. 26 (6): 259–268. doi:10.1002/bdd.458. PMID 15966026. S2CID 25596274.

Heinig R, Sundaresan P, Shah A, Boettcher M (2005). "Effect of gender and age on the pharmacokinetics of repinotan". Clinical Drug Investigation. 25 (2): 125–134. doi:10.2165/00044011-200525020-00005. PMID 17523762. S2CID 40485277.

Heinig R, Böttcher MF (2005). "Pharmacokinetics of escalating doses of intravenous repinotan in healthy male volunteers". Clinical Drug Investigation. 25 (2): 115–123. doi:10.2165/00044011-200525020-00004. PMID 17523761. S2CID 23415230.

Seidel D, Conrad M, Schoof Y, Schohe-Loop R (November 2002). "Synthesis of [14C]-labelled repinotan hydrochloride and its major metabolite M-6". Journal of Labelled Compounds and Radiopharmaceuticals. 45 (13): 1115–1132. doi:10.1002/jlcr.629.

Gross JL (November 2003). "A concise stereospecific synthesis of repinotan (BAY× 3702)". Tetrahedron Letters. 44 (47): 8563–8565. doi:10.1016/j.tetlet.2003.09.130.

espacenet.com

worldwide.espacenet.com

US 5300523, Junge B, Schohe R, Seidel PR, Glaser T, Traber J, Benz U, Schuurman T, De Vry JM, issued 1994, assigned to Bayer Healthcare AG.

US 5830908, Grunenberg A, Brehm O, Conrad M, Seidel D, issued 1998, assigned to Bayer AG.

handle.net

hdl.handle.net

nih.gov

pubmed.ncbi.nlm.nih.gov

De Vry J, Schohe-Loop R, Heine HG, Greuel JM, Mauler F, Schmidt B, et al. (March 1998). "Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist". The Journal of Pharmacology and Experimental Therapeutics. 284 (3): 1082–1094. PMID 9495870.

Dong J, de Montigny C, Blier P (September 1998). "Full agonistic properties of BAY x 3702 on presynaptic and postsynaptic 5-HT1A receptors electrophysiological studies in the rat hippocampus and dorsal raphe". The Journal of Pharmacology and Experimental Therapeutics. 286 (3): 1239–1247. PMID 9732384.

Lutsep HL (June 2002). "Repinotan Bayer". Current Opinion in Investigational Drugs. 3 (6): 924–927. PMID 12137415.

Kline AE, Yu J, Horváth E, Marion DW, Dixon CE (2001). "The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats". Neuroscience. 106 (3): 547–555. doi:10.1016/s0306-4522(01)00300-1. PMID 11591455. S2CID 54308982.

Ferro JM, Dávalos A (2006). "Other neuroprotective therapies on trial in acute stroke". Cerebrovascular Diseases. 21 Suppl 2 (2): 127–130. doi:10.1159/000091712. PMID 16651823. S2CID 39193793.

ncbi.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

"PubChem- Repinotan". PubChem. National Center for Biotechnology Information, U.S. National Library of Medicine. Retrieved 10 November 2014.

semanticscholar.org

api.semanticscholar.org

Kline AE, Yu J, Horváth E, Marion DW, Dixon CE (2001). "The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats". Neuroscience. 106 (3): 547–555. doi:10.1016/s0306-4522(01)00300-1. PMID 11591455. S2CID 54308982.

Ferro JM, Dávalos A (2006). "Other neuroprotective therapies on trial in acute stroke". Cerebrovascular Diseases. 21 Suppl 2 (2): 127–130. doi:10.1159/000091712. PMID 16651823. S2CID 39193793.

pdfs.semanticscholar.org

Repinotan (English Wikipedia)

doi.org

espacenet.com

worldwide.espacenet.com

handle.net

hdl.handle.net

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

pdfs.semanticscholar.org

web.archive.org